
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligators portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-PrimeTM, and novel drug candidates based on the RUBYTM bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator s technology platform comprises the proprietary technologies ALLIGATOR-GOLD and FIND. ALLIGATOR-GOLD is a human antibody library containing more...
Immunotherapy of cancer,immuno-oncology,cd40,and combination therapy
Alligator bioscience ab operates in the Biotechnology research industry.
Alligator bioscience ab's revenue is 1m - 10m
Alligator bioscience ab has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.